Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Casadó V[au]:

Targeting the dopamine D3 receptor: an overview of drug design strategies. Cortés A et al. Expert Opin Drug Discov. (2016)

G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. Ferré S et al. Pharmacol Rev. (2014)

Allosteric mechanisms within the adenosine A2A-dopamine D2 receptor heterotetramer. Ferré S et al. Neuropharmacology. (2016)

Search results

Items: 1 to 50 of 162

1.

Targeting the receptor-based interactome of the dopamine D1 receptor: looking for heteromer-selective drugs.

Casadó-Anguera V, Cortés A, Casadó V, Moreno E.

Expert Opin Drug Discov. 2019 Sep 11:1-16. doi: 10.1080/17460441.2019.1664469. [Epub ahead of print]

PMID:
31507210
2.

The heterotetrameric structure of the adenosine A1-dopamine D1 receptor complex: Pharmacological implication for restless legs syndrome.

Cortés A, Casadó-Anguera V, Moreno E, Casadó V.

Adv Pharmacol. 2019;84:37-78. doi: 10.1016/bs.apha.2019.01.001. Epub 2019 Feb 13.

PMID:
31229177
3.

The Endocannabinoid System as a Target in Cancer Diseases: Are We There Yet?

Moreno E, Cavic M, Krivokuca A, Casadó V, Canela E.

Front Pharmacol. 2019 Apr 5;10:339. doi: 10.3389/fphar.2019.00339. eCollection 2019. Review.

4.

Biased G Protein-Independent Signaling of Dopamine D1-D3 Receptor Heteromers in the Nucleus Accumbens.

Guitart X, Moreno E, Rea W, Sánchez-Soto M, Cai NS, Quiroz C, Kumar V, Bourque L, Cortés A, Canela EI, Bishop C, Newman AH, Casadó V, Ferré S.

Mol Neurobiol. 2019 Oct;56(10):6756-6769. doi: 10.1007/s12035-019-1564-8. Epub 2019 Mar 27.

PMID:
30919214
5.

Opioid-galanin receptor heteromers mediate the dopaminergic effects of opioids.

Cai NS, Quiroz C, Bonaventura J, Bonifazi A, Cole TO, Purks J, Billing AS, Massey E, Wagner M, Wish ED, Guitart X, Rea W, Lam S, Moreno E, Casadó-Anguera V, Greenblatt AD, Jacobson AE, Rice KC, Casadó V, Newman AH, Winkelman JW, Michaelides M, Weintraub E, Volkow ND, Belcher AM, Ferré S.

J Clin Invest. 2019 Mar 26;129(7):2730-2744. doi: 10.1172/JCI126912.

6.

Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer.

Blasco-Benito S, Moreno E, Seijo-Vila M, Tundidor I, Andradas C, Caffarel MM, Caro-Villalobos M, Urigüen L, Diez-Alarcia R, Moreno-Bueno G, Hernández L, Manso L, Homar-Ruano P, McCormick PJ, Bibic L, Bernadó-Morales C, Arribas J, Canals M, Casadó V, Canela EI, Guzmán M, Pérez-Gómez E, Sánchez C.

Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3863-3872. doi: 10.1073/pnas.1815034116. Epub 2019 Feb 7. Erratum in: Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6505.

7.

Reinterpreting anomalous competitive binding experiments within G protein-coupled receptor homodimers using a dimer receptor model.

Casadó-Anguera V, Moreno E, Mallol J, Ferré S, Canela EI, Cortés A, Casadó V.

Pharmacol Res. 2019 Jan;139:337-347. doi: 10.1016/j.phrs.2018.11.032. Epub 2018 Nov 22.

PMID:
30472462
8.

Revisiting the Functional Role of Dopamine D4 Receptor Gene Polymorphisms: Heteromerization-Dependent Gain of Function of the D4.7 Receptor Variant.

Sánchez-Soto M, Yano H, Cai NS, Casadó-Anguera V, Moreno E, Casadó V, Ferré S.

Mol Neurobiol. 2019 Jul;56(7):4778-4785. doi: 10.1007/s12035-018-1413-1. Epub 2018 Nov 1.

PMID:
30387076
9.

Design of a True Bivalent Ligand with Picomolar Binding Affinity for a G Protein-Coupled Receptor Homodimer.

Pulido D, Casadó-Anguera V, Pérez-Benito L, Moreno E, Cordomí A, López L, Cortés A, Ferré S, Pardo L, Casadó V, Royo M.

J Med Chem. 2018 Oct 25;61(20):9335-9346. doi: 10.1021/acs.jmedchem.8b01249. Epub 2018 Oct 11.

PMID:
30257092
10.

Acute and repeated dose (28 days) oral safety studies of phosphatidyl-hydroxytyrosol.

Martínez MA, Ares I, Martínez-Larrañaga MR, Anadón A, Casado V, Vazquez L, Martin D, Reglero G, Torres C.

Food Chem Toxicol. 2018 Oct;120:462-471. doi: 10.1016/j.fct.2018.07.046. Epub 2018 Jul 25.

PMID:
30055313
11.

Adenosine A1-Dopamine D1 Receptor Heteromers Control the Excitability of the Spinal Motoneuron.

Rivera-Oliver M, Moreno E, Álvarez-Bagnarol Y, Ayala-Santiago C, Cruz-Reyes N, Molina-Castro GC, Clemens S, Canela EI, Ferré S, Casadó V, Díaz-Ríos M.

Mol Neurobiol. 2019 Feb;56(2):797-811. doi: 10.1007/s12035-018-1120-y. Epub 2018 May 24.

PMID:
29797183
12.

Essential Control of the Function of the Striatopallidal Neuron by Pre-coupled Complexes of Adenosine A2A-Dopamine D2 Receptor Heterotetramers and Adenylyl Cyclase.

Ferré S, Bonaventura J, Zhu W, Hatcher-Solis C, Taura J, Quiroz C, Cai NS, Moreno E, Casadó-Anguera V, Kravitz AV, Thompson KR, Tomasi DG, Navarro G, Cordomí A, Pardo L, Lluís C, Dessauer CW, Volkow ND, Casadó V, Ciruela F, Logothetis DE, Zwilling D.

Front Pharmacol. 2018 Apr 9;9:243. doi: 10.3389/fphar.2018.00243. eCollection 2018.

13.

Evidence for functional pre-coupled complexes of receptor heteromers and adenylyl cyclase.

Navarro G, Cordomí A, Casadó-Anguera V, Moreno E, Cai NS, Cortés A, Canela EI, Dessauer CW, Casadó V, Pardo L, Lluís C, Ferré S.

Nat Commun. 2018 Mar 28;9(1):1242. doi: 10.1038/s41467-018-03522-3.

14.

Prevalence, risk factors and complications of oropharyngeal dysphagia in stroke patients: A cohort study.

Rofes L, Muriana D, Palomeras E, Vilardell N, Palomera E, Alvarez-Berdugo D, Casado V, Clavé P.

Neurogastroenterol Motil. 2018 Mar 23:e13338. doi: 10.1111/nmo.13338. [Epub ahead of print]

PMID:
29573064
15.

α2A- and α2C-Adrenoceptors as Potential Targets for Dopamine and Dopamine Receptor Ligands.

Sánchez-Soto M, Casadó-Anguera V, Yano H, Bender BJ, Cai NS, Moreno E, Canela EI, Cortés A, Meiler J, Casadó V, Ferré S.

Mol Neurobiol. 2018 Nov;55(11):8438-8454. doi: 10.1007/s12035-018-1004-1. Epub 2018 Mar 18.

PMID:
29552726
16.

Molecular Evidence of Adenosine Deaminase Linking Adenosine A2A Receptor and CD26 Proteins.

Moreno E, Canet J, Gracia E, Lluís C, Mallol J, Canela EI, Cortés A, Casadó V.

Front Pharmacol. 2018 Feb 15;9:106. doi: 10.3389/fphar.2018.00106. eCollection 2018.

17.

Cross-communication between Gi and Gs in a G-protein-coupled receptor heterotetramer guided by a receptor C-terminal domain.

Navarro G, Cordomí A, Brugarolas M, Moreno E, Aguinaga D, Pérez-Benito L, Ferre S, Cortés A, Casadó V, Mallol J, Canela EI, Lluís C, Pardo L, McCormick PJ, Franco R.

BMC Biol. 2018 Feb 28;16(1):24. doi: 10.1186/s12915-018-0491-x.

18.

Pivotal Role of Adenosine Neurotransmission in Restless Legs Syndrome.

Ferré S, Quiroz C, Guitart X, Rea W, Seyedian A, Moreno E, Casadó-Anguera V, Díaz-Ríos M, Casadó V, Clemens S, Allen RP, Earley CJ, García-Borreguero D.

Front Neurosci. 2018 Jan 8;11:722. doi: 10.3389/fnins.2017.00722. eCollection 2017.

19.

Cannabis Users Show Enhanced Expression of CB1-5HT2A Receptor Heteromers in Olfactory Neuroepithelium Cells.

Galindo L, Moreno E, López-Armenta F, Guinart D, Cuenca-Royo A, Izquierdo-Serra M, Xicota L, Fernandez C, Menoyo E, Fernández-Fernández JM, Benítez-King G, Canela EI, Casadó V, Pérez V, de la Torre R, Robledo P.

Mol Neurobiol. 2018 Aug;55(8):6347-6361. doi: 10.1007/s12035-017-0833-7. Epub 2018 Jan 2.

PMID:
29294249
20.

Singular Location and Signaling Profile of Adenosine A2A-Cannabinoid CB1 Receptor Heteromers in the Dorsal Striatum.

Moreno E, Chiarlone A, Medrano M, Puigdellívol M, Bibic L, Howell LA, Resel E, Puente N, Casarejos MJ, Perucho J, Botta J, Suelves N, Ciruela F, Ginés S, Galve-Roperh I, Casadó V, Grandes P, Lutz B, Monory K, Canela EI, Lluís C, McCormick PJ, Guzmán M.

Neuropsychopharmacology. 2018 Apr;43(5):964-977. doi: 10.1038/npp.2017.12. Epub 2017 Jan 19.

21.

Functional μ-Opioid-Galanin Receptor Heteromers in the Ventral Tegmental Area.

Moreno E, Quiroz C, Rea W, Cai NS, Mallol J, Cortés A, Lluís C, Canela EI, Casadó V, Ferré S.

J Neurosci. 2017 Feb 1;37(5):1176-1186. doi: 10.1523/JNEUROSCI.2442-16.2016. Epub 2016 Dec 22.

23.

Predictors for mortality due to acute exacerbation of COPD in primary care: protocol for the derivation of a clinical prediction rule.

Alameda C, Carlos Matía Á, Casado V.

NPJ Prim Care Respir Med. 2016 Oct 20;26:16070. doi: 10.1038/npjpcrm.2016.70. No abstract available.

24.

Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease.

Guitart X, Bonaventura J, Rea W, Orrú M, Cellai L, Dettori I, Pedata F, Brugarolas M, Cortés A, Casadó V, Chang CP, Narayanan M, Chern Y, Ferré S.

Neurobiol Dis. 2016 Dec;96:47-53. doi: 10.1016/j.nbd.2016.08.013. Epub 2016 Aug 24.

25.

Heteroreceptor Complexes Formed by Dopamine D1, Histamine H3, and N-Methyl-D-Aspartate Glutamate Receptors as Targets to Prevent Neuronal Death in Alzheimer's Disease.

Rodríguez-Ruiz M, Moreno E, Moreno-Delgado D, Navarro G, Mallol J, Cortés A, Lluís C, Canela EI, Casadó V, McCormick PJ, Franco R.

Mol Neurobiol. 2017 Aug;54(6):4537-4550. doi: 10.1007/s12035-016-9995-y. Epub 2016 Jul 1.

PMID:
27370794
26.

Targeting the dopamine D3 receptor: an overview of drug design strategies.

Cortés A, Moreno E, Rodríguez-Ruiz M, Canela EI, Casadó V.

Expert Opin Drug Discov. 2016 Jul;11(7):641-64. doi: 10.1080/17460441.2016.1185413. Epub 2016 May 30. Review.

PMID:
27135354
27.

A Significant Role of the Truncated Ghrelin Receptor GHS-R1b in Ghrelin-induced Signaling in Neurons.

Navarro G, Aguinaga D, Angelats E, Medrano M, Moreno E, Mallol J, Cortés A, Canela EI, Casadó V, McCormick PJ, Lluís C, Ferré S.

J Biol Chem. 2016 Jun 17;291(25):13048-62. doi: 10.1074/jbc.M116.715144. Epub 2016 Apr 25.

28.

Evidence for the heterotetrameric structure of the adenosine A2A-dopamine D2 receptor complex.

Casadó-Anguera V, Bonaventura J, Moreno E, Navarro G, Cortés A, Ferré S, Casadó V.

Biochem Soc Trans. 2016 Apr 15;44(2):595-600. doi: 10.1042/BST20150276. Review.

PMID:
27068975
29.

Quaternary structure of a G-protein-coupled receptor heterotetramer in complex with Gi and Gs.

Navarro G, Cordomí A, Zelman-Femiak M, Brugarolas M, Moreno E, Aguinaga D, Perez-Benito L, Cortés A, Casadó V, Mallol J, Canela EI, Lluís C, Pardo L, García-Sáez AJ, McCormick PJ, Franco R.

BMC Biol. 2016 Apr 5;14:26. doi: 10.1186/s12915-016-0247-4.

30.

Carbon regulation of environmental pH by secreted small molecules that modulate pathogenicity in phytopathogenic fungi.

Bi F, Barad S, Ment D, Luria N, Dubey A, Casado V, Glam N, Mínguez JD, Espeso EA, Fluhr R, Prusky D.

Mol Plant Pathol. 2016 Oct;17(8):1178-95. doi: 10.1111/mpp.12355. Epub 2016 Apr 12.

PMID:
26666972
31.

Hints on the Lateralization of Dopamine Binding to D1 Receptors in Rat Striatum.

Franco R, Casadó-Anguera V, Muñoz A, Petrovic M, Navarro G, Moreno E, Lanciego JL, Labandeira-García JL, Cortés A, Casadó V.

Mol Neurobiol. 2016 Oct;53(8):5436-45. doi: 10.1007/s12035-015-9468-8. Epub 2015 Oct 9.

PMID:
26452359
32.

Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer.

Madoz-Gúrpide J, Zazo S, Chamizo C, Casado V, Caramés C, Gavín E, Cristóbal I, García-Foncillas J, Rojo F.

J Transl Med. 2015 Aug 29;13:282. doi: 10.1186/s12967-015-0633-7.

33.

Allosteric interactions between agonists and antagonists within the adenosine A2A receptor-dopamine D2 receptor heterotetramer.

Bonaventura J, Navarro G, Casadó-Anguera V, Azdad K, Rea W, Moreno E, Brugarolas M, Mallol J, Canela EI, Lluís C, Cortés A, Volkow ND, Schiffmann SN, Ferré S, Casadó V.

Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):E3609-18. doi: 10.1073/pnas.1507704112. Epub 2015 Jun 22.

34.

Allosteric mechanisms within the adenosine A2A-dopamine D2 receptor heterotetramer.

Ferré S, Bonaventura J, Tomasi D, Navarro G, Moreno E, Cortés A, Lluís C, Casadó V, Volkow ND.

Neuropharmacology. 2016 May;104:154-60. doi: 10.1016/j.neuropharm.2015.05.028. Epub 2015 Jun 4. Review.

35.

A solid-phase combinatorial approach for indoloquinolizidine-peptides with high affinity at D(1) and D(2) dopamine receptors.

Molero A, Vendrell M, Bonaventura J, Zachmann J, López L, Pardo L, Lluis C, Cortés A, Albericio F, Casadó V, Royo M.

Eur J Med Chem. 2015 Jun 5;97:173-80. doi: 10.1016/j.ejmech.2015.04.052. Epub 2015 Apr 28.

36.

Orexin-corticotropin-releasing factor receptor heteromers in the ventral tegmental area as targets for cocaine.

Navarro G, Quiroz C, Moreno-Delgado D, Sierakowiak A, McDowell K, Moreno E, Rea W, Cai NS, Aguinaga D, Howell LA, Hausch F, Cortés A, Mallol J, Casadó V, Lluís C, Canela EI, Ferré S, McCormick PJ.

J Neurosci. 2015 Apr 29;35(17):6639-53. doi: 10.1523/JNEUROSCI.4364-14.2015.

37.

Caffeine increases striatal dopamine D2/D3 receptor availability in the human brain.

Volkow ND, Wang GJ, Logan J, Alexoff D, Fowler JS, Thanos PK, Wong C, Casado V, Ferre S, Tomasi D.

Transl Psychiatry. 2015 Apr 14;5:e549. doi: 10.1038/tp.2015.46.

38.

Laryngeal measurements and diagnostic tools for diagnosis of chronic obstructive pulmonary disease.

Casado V, Navarro SM, Alvarez AE, Villafañe M, Miranda A, Spaans N; Research Group ParquEPOC.

Ann Fam Med. 2015 Jan-Feb;13(1):49-52. doi: 10.1370/afm.1733.

39.

Intracellular calcium levels determine differential modulation of allosteric interactions within G protein-coupled receptor heteromers.

Navarro G, Aguinaga D, Moreno E, Hradsky J, Reddy PP, Cortés A, Mallol J, Casadó V, Mikhaylova M, Kreutz MR, Lluís C, Canela EI, McCormick PJ, Ferré S.

Chem Biol. 2014 Nov 20;21(11):1546-56. doi: 10.1016/j.chembiol.2014.10.004.

40.

Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia.

Farré D, Muñoz A, Moreno E, Reyes-Resina I, Canet-Pons J, Dopeso-Reyes IG, Rico AJ, Lluís C, Mallol J, Navarro G, Canela EI, Cortés A, Labandeira-García JL, Casadó V, Lanciego JL, Franco R.

Mol Neurobiol. 2015 Dec;52(3):1408-1420. doi: 10.1007/s12035-014-8936-x. Epub 2014 Oct 26.

PMID:
25344317
41.

Phosphatidyl derivative of hydroxytyrosol. In vitro intestinal digestion, bioaccessibility, and its effect on antioxidant activity.

Martin D, Moran-Valero MI, Casado V, Reglero G, Torres CF.

J Agric Food Chem. 2014 Oct 8;62(40):9751-9. doi: 10.1021/jf503477h. Epub 2014 Sep 25.

PMID:
25255083
42.

Functional selectivity of allosteric interactions within G protein-coupled receptor oligomers: the dopamine D1-D3 receptor heterotetramer.

Guitart X, Navarro G, Moreno E, Yano H, Cai NS, Sánchez-Soto M, Kumar-Barodia S, Naidu YT, Mallol J, Cortés A, Lluís C, Canela EI, Casadó V, McCormick PJ, Ferré S.

Mol Pharmacol. 2014 Oct;86(4):417-29. doi: 10.1124/mol.114.093096. Epub 2014 Aug 5.

43.

Moonlighting adenosine deaminase: a target protein for drug development.

Cortés A, Gracia E, Moreno E, Mallol J, Lluís C, Canela EI, Casadó V.

Med Res Rev. 2015 Jan;35(1):85-125. doi: 10.1002/med.21324. Epub 2014 Jun 16. Review.

PMID:
24933472
44.

G-protein-coupled receptor heteromers as key players in the molecular architecture of the central nervous system.

Brugarolas M, Navarro G, Martínez-Pinilla E, Angelats E, Casadó V, Lanciego JL, Franco R.

CNS Neurosci Ther. 2014 Aug;20(8):703-9. doi: 10.1111/cns.12277. Epub 2014 May 9. Review.

45.

Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy.

del Puerto-Nevado L, Rojo F, Zazo S, Caramés C, Rubio G, Vega R, Chamizo C, Casado V, Martínez-Useros J, Rincón R, Rodríguez-Remírez M, Borrero-Palacios A, Cristóbal I, Madoz-Gúrpide J, Aguilera O, García-Foncillas J.

Br J Cancer. 2014 May 27;110(11):2700-7. doi: 10.1038/bjc.2014.225. Epub 2014 May 1.

46.

Cocaine disrupts histamine H3 receptor modulation of dopamine D1 receptor signaling: σ1-D1-H3 receptor complexes as key targets for reducing cocaine's effects.

Moreno E, Moreno-Delgado D, Navarro G, Hoffmann HM, Fuentes S, Rosell-Vilar S, Gasperini P, Rodríguez-Ruiz M, Medrano M, Mallol J, Cortés A, Casadó V, Lluís C, Ferré S, Ortiz J, Canela E, McCormick PJ.

J Neurosci. 2014 Mar 5;34(10):3545-58. doi: 10.1523/JNEUROSCI.4147-13.2014.

47.

G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives.

Ferré S, Casadó V, Devi LA, Filizola M, Jockers R, Lohse MJ, Milligan G, Pin JP, Guitart X.

Pharmacol Rev. 2014 Feb 10;66(2):413-34. doi: 10.1124/pr.113.008052. Print 2014. Review.

48.

L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.

Pinna A, Bonaventura J, Farré D, Sánchez M, Simola N, Mallol J, Lluís C, Costa G, Baqi Y, Müller CE, Cortés A, McCormick P, Canela EI, Martínez-Pinilla E, Lanciego JL, Casadó V, Armentero MT, Franco R.

Exp Neurol. 2014 Mar;253:180-91. doi: 10.1016/j.expneurol.2013.12.021. Epub 2014 Jan 9.

PMID:
24412491
49.

L-DOPA-treatment in primates disrupts the expression of A(2A) adenosine-CB(1) cannabinoid-D(2) dopamine receptor heteromers in the caudate nucleus.

Bonaventura J, Rico AJ, Moreno E, Sierra S, Sánchez M, Luquin N, Farré D, Müller CE, Martínez-Pinilla E, Cortés A, Mallol J, Armentero MT, Pinna A, Canela EI, Lluís C, McCormick PJ, Lanciego JL, Casadó V, Franco R.

Neuropharmacology. 2014 Apr;79:90-100. doi: 10.1016/j.neuropharm.2013.10.036. Epub 2013 Nov 11.

PMID:
24230991
50.

[Promote the autonomy and safety of the elderly: basic care].

Casado VI, Iglesias GJ, Postigo Mota S.

Rev Enferm. 2013 Jun;36(6):54-9. Spanish.

PMID:
23909224

Supplemental Content

Loading ...
Support Center